Khaled Musallam/LinkedIn
Sep 28, 2025, 08:41
Khaled Musallam Explores Molecular Understanding of β-Thalassemia at The 2nd Abu Dhabi Hematology Annual Review
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”Great program and talks during the 2nd Abu Dhabi Hematology Annual Review.
Thanks Dr Kayane Mheidly and Sheikh Shakhbout Medical City – SSMC for giving the stage to thalassemia.”
Stay updated with Hemostasis Today.
-
Feb 16, 2026, 06:21C. Michael Gibson: Favorable Safety Outcomes With Asundexian
-
Feb 16, 2026, 06:18Jecko Thachil: What Do Clinicians Mean by “Coagulopathy”?
-
Feb 16, 2026, 06:04Inside 2026 Highlights of ASH in the Mediterranean, Middle East, and North Africa with Dr. Heghine Khachatryan
-
Feb 15, 2026, 10:56Don’t Miss PNH: Clinical Practice From ISTH – Medscape
-
Feb 15, 2026, 10:52Awareness and Research on Factor V Deficiency Are Critical – EHC
-
Feb 15, 2026, 10:43Peter Zdziarski: Protecting Patient Data in the Rare Disease Community
-
Feb 15, 2026, 10:31Michiel Voet: The Price Tag of a Whole Blood Strategy
-
Feb 15, 2026, 10:26Sifat Jubaira: K₂-EDTA vs K₃-EDTA – Same Anticoagulant, Very Different Accuracy
-
Feb 15, 2026, 09:29Gevorg Tamamyan: Childhood Cancer is Curable. Inequity Is Not